Financhill
Back

Pieris Pharmaceuticals Quote, Financials, Valuation and Earnings

Yours Free! Top SIX AI Dividend Stocks Right Now

NO CREDIT CARD REQUIRED!
Sell
45

PIRS
Pieris Pharmaceuticals

Last Price:
17.00
Seasonality Move:
9.58%

7 Day Trial

ALL ACCESS PASS

$ 7

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade

Pieris Pharmaceuticals Price Quote

$17.00

Pieris Pharmaceuticals Key Stats

Sell
45
Pieris Pharmaceuticals (PIRS) is a Sell

Day range:
$16.88 - $17.26
52-week range:
$6.20 - $23.20
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.52
P/B ratio:
1.2%

Volume:
14.2K
Avg. volume:
7.7K
1-year change:
-18.46%
Market cap:
$22.4M
Revenue:
$42.8M
EPS:
$-18.71

How Much Does Pieris Pharmaceuticals Make?

Data Unavailable

Is Pieris Pharmaceuticals Growing As A Company?

Data Unavailable

Pieris Pharmaceuticals Stock Price Performance

What Is Pieris Pharmaceuticals 52-Week High & Low?

Pieris Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Pieris Pharmaceuticals?

Is Pieris Pharmaceuticals Cash Flow Positive?

  • What Is PIRS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$37.9M
  • What Is Pieris Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $0
  • What Is Pieris Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $12.6M

Pieris Pharmaceuticals Return On Invested Capital

Data Unavailable

Pieris Pharmaceuticals Earnings Date & Stock Price

Pieris Pharmaceuticals Competitors

Pieris Pharmaceuticals Dividend Yield

Pieris Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 152.07%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 560.00
Upside from Last Price: 3194.12%

Major Shareholders

  • How many PIRS shares are owned by institutional investors?
    31M PIRS shares are owned by institutional investors
  • How many PIRS shares are owned by insiders?
    121.7K PIRS shares are owned by insiders